Hormone Insight

FWA
  • 0.0 (0)
  • Education

Discuss Diabetes and Endocrinology studies in a simplified manner. Expand your knowledge in Diabetes and Endocrinology.

  1. 10h ago

    GRASS: Selenium in Graves' | Hormone Insight Podcast

    Does selenium supplementation benefit people with newly diagnosed Graves' hyperthyroidism? In the GRASS randomised trial, selenium did not improve remission rates or quality of life compared with placebo. Randomised trial · European Thyroid Journal 2026 Reference: Cramon P, et al. Selenium supplementation in individuals with newly diagnosed Graves' hyperthyroidism: a double-blind, multicentre RCT. Eur Thyroid J. 2026;15(1). doi:10.1530/ETJ-25-0264. PMID: 41384622. https://pubmed.ncbi.nlm.nih.gov/41384622/ AI-narrated episode. For healthcare professionals; educational only and not medical advice. Hormone Insight: https://hormoneinsight.com/ Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

  2. 1d ago

    ESTIMABL2: No radioiodine at 5 years | Hormone Insight Podcast

    What happens at 5 years of follow-up with thyroidectomy without radioiodine in patients with low-risk thyroid cancer? In patients with low-risk differentiated thyroid cancer, a follow-up strategy without radioiodine was non-inferior to postoperative radioiodine at 5 years. Randomized trial · Lancet Diabetes Endocrinol 2025 Reference: Leboulleux. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial. The Lancet Diabetes & Endocrinology. 2025;13(1):38–46. doi:10.1016/S2213-8587(24)00276-6. PMID:39586309. Chapters 0:00 Intro 0:38 The trial 3:19 My take 3:50 Outro Read the structured trial summary at https://hormoneinsight.com AI narration is used. This podcast is intended for healthcare professionals only. It is educational, not medical advice. Views expressed are the presenter’s own and do not necessarily reflect those of any institution he works with. Hormone Insight: https://hormoneinsight.com Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

  3. 2d ago

    IoN: Skip radioiodine? | Hormone Insight Podcast

    After thyroidectomy for low-risk differentiated thyroid cancer, is omission of postoperative radioiodine non-inferior to ablation? In the IoN randomised trial, omission of postoperative radioiodine was noninferior to ablation for 5-year recurrence-free survival. Randomised multicentre non-inferiority trial · The Lancet 2025 Reference: Mallick U, et al. Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN). Lancet. 2025;406(10498):52-62. doi:10.1016/S0140-6736(25)00629-4. PMID: 40543520. https://pubmed.ncbi.nlm.nih.gov/40543520/ This is a summary of trial findings, not an individual treatment recommendation. AI-narrated episode. For healthcare professionals; educational only and not medical advice. Hormone Insight: https://hormoneinsight.com/ Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

  4. 3d ago

    Rosiglitazone: A heart attack signal? | Hormone Insight Podcast

    Does rosiglitazone increase myocardial infarction or cardiovascular-death risk in type 2 diabetes? A 2007 meta-analysis found a higher risk of myocardial infarction than control, with a borderline increase in cardiovascular death. Meta-analysis · New England Journal of Medicine 2007 Reference: Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471. AI-narrated episode. For healthcare professionals; educational only and not medical advice. Hormone Insight: https://hormoneinsight.com/ Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

  5. 4d ago

    Closed-loop under 7: Automated insulin delivery | Hormone Insight Podcast

    Does automated insulin delivery improve glucose control in children under 7 with type 1 diabetes? A 2026 meta-analysis reported improved time in range and HbA1c compared with standard care over 8 to 16 weeks. Meta-analysis · Diabetic Medicine 2026 Reference: Lin Q, Zhou Y, Lei M, et al. Diabet Med. 2026;43(7):e70354. doi:10.1111/dme.70354. PMID:42108409. https://pubmed.ncbi.nlm.nih.gov/42108409/ Chapters 0:00 Intro 0:38 The study 3:01 What this means 3:31 Outro Read the structured trial summary at https://hormoneinsight.com/ AI-narrated. For healthcare professionals; educational only and not medical advice. Hormone Insight: https://hormoneinsight.com/ Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

  6. 5d ago

    GRADE: Fewer admissions? Not so fast | Hormone Insight Podcast

    Does liraglutide reduce hospitalization risk compared with glimepiride in people with type 2 diabetes on metformin? In GRADE participants with type 2 diabetes on metformin, time to first hospitalization did not differ overall by glucose-lowering drug; liraglutide modestly reduced subsequent hospitalization risk versus glimepiride on assigned treatment. Secondary analysis of a randomised trial · Diabetes Care 2025 Reference: Hsia DS, Younes N, Ghosh A. Diabetes Care. 2025. PMID: 40424051. https://pubmed.ncbi.nlm.nih.gov/40424051/ AI-narrated episode. For healthcare professionals; educational only and not medical advice. Hormone Insight: https://hormoneinsight.com/ iPhone/iPad app: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Android app: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

  7. 6d ago

    SURPASS-4: Tirzepatide and the kidney | Hormone Insight Podcast

    Does tirzepatide improve kidney outcomes compared with insulin glargine in type 2 diabetes with high cardiovascular risk? In people with type 2 diabetes and high cardiovascular risk, tirzepatide slowed eGFR decline and reduced albuminuria more than insulin glargine over a median 85 weeks. This was a secondary analysis of a randomised trial. Reference: Heerspink HJL, Sattar N, Pavo I, et al. Lancet Diabetes Endocrinol. 2022. PMID: 36152639. https://pubmed.ncbi.nlm.nih.gov/36152639/ AI-narrated episode. For healthcare professionals; educational only and not medical advice. Hormone Insight: https://hormoneinsight.com/ iPhone/iPad app: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Android app: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

  8. Oct 10

    SOUL: Oral semaglutide and the heart | Hormone Insight Podcast

    Does oral semaglutide reduce major adverse cardiovascular events in high-risk type 2 diabetes patients? In people with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, oral semaglutide reduced major adverse cardiovascular events compared with placebo. Randomized trial · NEJM 2025 Reference: McGuire DK, Marx N, Mulvagh SL. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025; PMID:40162642. Chapters 0:00 Intro 0:38 The trial 3:07 My take 3:49 Outro Read the structured trial summary at https://hormoneinsight.com/ AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with. Explore Hormone Insight: Website: https://hormoneinsight.com/ Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856 Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

See All (37)

About

Discuss Diabetes and Endocrinology studies in a simplified manner. Expand your knowledge in Diabetes and Endocrinology.

Information

  • Creator
    FWA
  • Years Active
    2025 - 2026
  • Episodes
    37
  • Rating
    Clean
  • Copyright
    © Copyright 2024 FWA
  • Show Website
    Hormone Insight